Solid-phase synthesis and anti-bacterial evaluation of cyclic lipopeptide antibiotics
Solid-phase synthesis and anti-bacterial evaluation of cyclic lipopeptide antibiotics
批准号:
EP/D041015/1
负责人:
John Malkinson
金额:
$15.93万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2007
资助国家:
英国
项目状态:
已结题
起止时间:
2007 至 --
中文摘要
对人类健康的主要威胁之一是细菌等微生物的感染。为了杀死导致感染的细菌,药物治疗是第一道防线。由于细菌细胞和人类细胞之间的差异,已经开发出了有效的药物。通过利用这些差异,我们可以杀死细菌细胞,治疗感染,而不会对感染者造成伤害。不幸的是,我们针对细菌和人类之间差异的方法有限,因此,我们可以制造的不同类型抗生素药物的数量是有限的。目前有很多研究都在研究能以不同方式杀死细菌细胞的新药。过度使用抗生素会导致细菌产生耐药性。细菌分裂迅速,产生的新细菌细胞与产生它们的细胞不完全相同。细菌细胞每次自我复制时,复制的东西都不是完美的:新细胞会有一些细微的不同。有时,细菌分裂时出现的这些微小差异意味着它们不再被抗生素杀死:这种微小差异影响了抗生素起作用的细菌细胞部分。所以如果有人感染用抗生素治疗,抗生素会杀死几乎所有的细菌,但可能还有一些不受抗生素影响的剩余细菌。这些存活下来的细菌开始不断分裂,直到出现新的感染,但这一次,细菌对抗生素产生了耐药性。我们使用的大多数抗生素已经存在很长时间了,所以有些细菌对几乎所有抗生素都有抗药性。最著名的耐药细菌是MRSA,它每年造成许多人死于医院感染。已知药物和新药的最佳来源之一是大自然。许多抗生素药物最初是从真菌(如青霉素)或其他细菌中分离出来的。细菌经常产生抗生素作为一种自我防御机制来杀死其他细菌。最近获准使用的一种新型抗生素是达托霉素。达托霉素杀灭细菌的新方法;它会干扰细菌的细胞壁,导致细菌的内容物泄漏出来。由于达托霉素以一种新的方式起作用,它可以杀死对所有其他抗生素都有抗药性的细菌。发现以新方式起作用的抗生素非常重要,因为它使我们能够治疗可能危及生命的耐药感染。达托霉素是由一环氨基酸(构成蛋白质的基石)组成的,上面附着着一小块脂肪。该研究项目将开发一种合成生产达托霉素的方法,而不是从细菌中提取和生产达托霉素。我们将使用这些氨基酸逐步建立连接在小塑料珠上的结构。一旦分子完成,它将从头部取出并纯化。我们将使用同样的方法对抗生素的结构进行微小的改变,以观察药物分子的哪些部分对其作为抗生素的活性很重要。我们还将使用开发的方法来合成其他细菌产生的其他类似抗生素,看看它们是否具有类似的活性。有许多不同种类的抗生素与达托霉素非常相似,可能是非常有用的药物,但它们尚未得到任何详细的研究。我们生产的所有抗生素都要经过杀菌能力测试,包括耐甲氧西林金黄色葡萄球菌。这项研究项目将为我们提供一种制造这些抗生素的新方法,并将帮助我们了解它们的工作原理。它还将使我们能够开发出新的抗生素,这些抗生素最终可能会用于治疗危及生命的感染。
英文摘要
SummaryOne of the principal threats to human health is infection by micro-organisms such as bacteria. Drug treatment is the first line of attack in order to kill the bacteria that are responsible for causing the infection. Drugs have been developed that work as a result of the differences between bacterial cells and human cells. By exploiting these differences, we can kill the bacterial cells and treat the infection without causing damage to the person that is infected. Unfortunately, there are a limited number of ways that we can target the differences between bacteria and humans and, so, there is a limit to the number of different types of antibiotic drugs that we can make. There is a lot of current research into new drugs that can kill bacterial cells in different ways.Over-use of antibiotics can cause bacteria to become resistant. Bacteria divide rapidly and the new bacterial cells that are produced are never exactly the same at the cells that they were produced from. Each time a bacterial cell copies itself, the copy is not perfect : there will be something very slightly different about the new cell. Sometimes these small differences that occur when the bacteria divide mean that they are no longer killed by an antibiotic: the small difference affects the part of the bacterial cell where the antibiotic works. So if someone with an infection is treated with an antibiotic, the antibiotic will kill nearly all of the bacteria, but there may be some left over that are not affected by the antibiotic. These survivors can then begin to divide and divide until there is a new infection, but this time, the bacteria are resistant to the antibiotic. Most of the antibiotics that we use have been around for a very long time, so there are some bacteria that are resistant to nearly all of them. The most well known of the resistant bacteria that is responsible for many deaths each year from infections acquired in hospitals is MRSA.One of the best sources of well-known and new drugs is nature. Many antibiotic drugs were first isolated from fungi (e.g. penicillin) or from other bacteria. Bacteria often produce antibiotics as a self-defence mechanism to kill other bacteria. One such new antibiotic that has recently been licensed for use is daptomycin. Daptomycin kills bacteria in a new way; it interferes will the bacterial cell wall causing the contents of the bacteria to leak out. Since daptomycin works in a new way, it can kill bacteria that are resistant to all other antibiotics. Finding antibiotics that work in new ways is very important as it allows us to treat resistant infections that may otherwise be life-threatening.Daptomycin is made up from a ring of amino acids (the building blocks that make up proteins) to which a small fat is attached. Rather than extract and produce daptomycin from bacteria, this research project will develop a method to produce it synthetically. We will build-up the structure attached to small plastic beads using these amino acids in a stepwise manner. Once the molecule is finished, it will be removed from the bead and purified. We will use the same method to make small changes to the structure of the antibiotic to see which parts of the drug molecule are important for its activity as an antibiotic. We will also use the methods developed to synthesise other, similar antibiotics that are produced by other bacteria, to see if they have similar activity. There are many different kinds of antibiotics very similar to daptomycin that may be very useful drugs, but they have yet to be studied in any detail. All of the antibiotics that we produce will be tested for their ability to kill bacteria, including MRSA.This research project will give us a new method of making these antibiotics and will help us to understand how they work. It will also allow us to develop new antibiotics that may eventually be useful as drugs to treat life-threatening infections in patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
Baryogenesis, Dark Matter and Nanohertz Gravitational Waves from a Dark
Supercooled Phase Transition
-
批准号:24ZR1429700
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:YUICHIRO NAKAI
-
依托单位:
含Re、Ru先进镍基单晶高温合金中TCP相成核—生长机理的原位动态研究
-
批准号:52301178
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:夏万顺
-
依托单位:
均相液相生物芯片检测系统的构建及其在癌症早期诊断上的应用
-
批准号:82372089
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:李万万
-
依托单位:
PCBP1和PCBP2调控cGAS的相变和酶活的机制研究
-
批准号:32370928
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:孙钦秒
-
依托单位:
HNRNPK-Xist液液相分离促进X染色体失活
-
批准号:32100547
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2021
-
负责人:丁明瑞
-
依托单位:
Dishevelled相分离对Wnt信号通路转导及功能影响的研究
-
批准号:32100566
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:石巧妮
-
依托单位:
SMN驱动神经细胞轴突中mRNA转运核糖核蛋白形成的分子机制
-
批准号:32100548
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:王羚瑶
-
依托单位:
Rbm14的相分离在胚胎发育中的功能及作用机理研究
-
批准号:32000556
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:肖悦
-
依托单位:
蛋白质液-液相变环境中DNA G-四链体结构的形成与功能研究
-
批准号:32000866
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:李新敏
-
依托单位:
纺锤体装配与染色体向子细胞中平均分配的调控机理研究
-
批准号:32070714
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:辛广伟
-
依托单位: